Immunotherapy or molecularly targeted therapy: What is the best initial treatment for stage IV BRAF-mutant melanoma?

Clinical Advances in Hematology and Oncology

Volumn 13, Issue 7, 2015, Pages

  Gibney, Geoffrey T ^a   Atkins, Michael B ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

BRAF mutations; Checkpoint inhibitors; Immunotherapy; Melanoma; Targeted therapy

Indexed keywords

B RAF KINASE; BRAF INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN;

ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; DRUG EFFICACY; DRUG SAFETY; GENE; GENE MUTATION; HUMAN; IMMUNOTHERAPY; LONG TERM SURVIVAL; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; VISCERAL METASTASIS; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84937485299     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013;19(16):4326-4334.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.
4. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 doseescalation trial. Lancet. 2012;379(9829):1893-1901.
5. Carlino MS, Saunders CA, Haydu LE, et al. (18)F-labelled fluorodeoxyglucosepositron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Eur J Cancer. 2013;49(2):395-402.
6. Mc Arthur GA, Puzanov I, Amaravadi R, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012;30(14):1628-1634.
7. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
8. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
9. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323-332.
10. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM) [ASCO abstract 9013]. J Clin Oncol. 2013;31(15)(suppl).
11. Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 2012;22(3):177-183.
12. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-1095.
13. Kefford RF, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study [Society for Melanoma Research]. Pigment Cell Melanoma Res. 2013;26(6):965.
14. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10(7):390-399.
15. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
16. Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20(7):1965-1977.
17. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
18. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888.
19. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.
20. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.
21. Flaherty K, Daud A, Weber JS, et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM) [ASCO abstract 9010]. J Clin Oncol. 2014;32(5)(suppl).
22. Hodi FS, O’Day SJ, Mc Dermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
23. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;JCO.2014.56.2736.
24. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.
25. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
26. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697.
27. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117.
28. Ribas A, Puzanov I, Dummer R, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory (IPI-R) melanoma (MEL) [Society for Melanoma Research LBA]. Pigment Cell Melanoma Res. 2014;27(6).
29. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
30. Hodi FS, Kluger HM, Sznol M, et al. Long-term survival of ipilimumabnaive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in a phase 1 trial [Society for Melanoma Research]. Pigment Cell Melanoma Res. 2014;27(6):1199.
31. Weber JS, Minor DR, D’Angelo S, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after anti- CTLA-4 therapy [ESMO abstract LBA3]. Ann Oncol. 2014;25(5):1-41.
32. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
33. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma [published online April 19, 2015]. N Engl J Med.
34. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
35. Kluger HM, Sznol M, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL) [Society for Melanoma Research]. Pigment Cell Melanoma Res. 2014;27(6):1203.
36. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017.
37. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [published online May 31, 2015]. N Engl J Med. doi:10.1056/NEJMoa1504030.
38. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
39. Topalian SL, Sznol M, Mc Dermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030.
40. Ackerman A, Klein O, Mc Dermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695-1701.
41. Ascierto PA, Simeone E, Sileni VC, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest. 2014;32(4):144-149.
42. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588-598.
43. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®). Melanoma. v.3.2015. http://www.nccn.org/professionals/physiciangls/fguidelines.asp#site. Updated March 11,2015. Accessed May 26, 2015.